Spots Global Cancer Trial Database for Study of PM060184 in Patients With Advanced Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of PM060184 in Patients With Advanced Solid Tumors
Official Title: Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Study ID: NCT01299636
Conditions
Interventions
Study Description
Brief Summary: The purpose of the study is to determine the maximum tolerated dose and the recommended dose and to evaluate the safety and tolerability of PM060184.
Detailed Description: This trial intends to determine the maximum tolerated dose and the recommended dose, to evaluate the safety and tolerability, to determine the pharmacokinetics and to evaluate the antitumor activity of PM060184 in patients with advanced solid tumors.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
START- South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Contact Details
Name: Kyriakos Papadopoulos, MD
Affiliation: START- South Texas Accelerated Research Therapeutics, LLC
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
